Navegando por Assunto "Rifampicina"

Agora exibindo 1 - 2 de 2

Acesso aberto (Open Access)
Concentrações plasmáticas de rifampicina em pacientes com tuberculose pulmonar
(Universidade Federal do Pará, 2017-12-01) BELEZA, Breno Kristoffer Uchôa; VIEIRA, José Luiz Fernandes; http://lattes.cnpq.br/2739079559531098
Tuberculosis is an infectious-contagious disease that is still considered a major public health problem worldwide. Brazil is one of the 22 countries in the world responsible for 80% of the cases of the disease, and the highest incidence rates are observed in the North, Southeast and Northeast regions. The standard treatment regimen is composed of rifampicin, isoniazid, pyrazinamide and ethambutol. The clinical outcome is associated with the blood concentrations of these drugs after the use of therapeutic doses, however, despite the high incidence of the Brazilian disease, the concentrations of these drugs have not been evaluated in these patients, which is relevant mainly for rifampicin, given the high variability of concentrations in biological fluids after therapy. Therefore, a prospective case study was carried out to determine the concentrations of rifampicin by high performance liquid chromatography in patients with active tuberculosis treated in the city of Belém. Fifty patients were included in the study, however, there was a loss of clinical follow-up of 20 patients (40%), whose main reason was the abandonment of treatment. The social and demographic aspects of the others indicate a higher occurrence of the disease in males, low education, residents in the metropolitan area of Belém and in the productive age group. Rifampicin concentrations in the two treatment phases ranged from 0.6 μg / ml to 0.73 μg / ml. There was no significant difference in blood drug concentrations between treatment phases, however, rifampicin levels were significantly higher in women.
Acesso aberto (Open Access)
Concentrações séricas de rifampicina e glicemia em pacientes com tuberculose pulmonar ativa
(Universidade Federal do Pará, 2019-08-30) FONSECA, Adriana Aparecida Durães; VIEIRA, José Luiz Fernandes; http://lattes.cnpq.br/2739079559531098; https://orcid.org/ 0000-0003-4842-8762
Tuberculosis is a chronic disease caused by Mycobacterium tuberculosis, is considered an important public health issue in Brazil with approximately 70 to 90 thousand cases reported each year. The rates of incidences of chronic comorbidities associated with obesity increased in the last years, and, consequently, the coexistence of tuberculosis and diabetes mellitus also increase. There is an interesting interaction between these chronic diseases, as diabetes mellitus alter the immune response to infection and the pharmacokinetics of anti-tuberculosis drugs, and tuberculosis difficult the glycemic control in patients with diabetes. The aim of the study was to investigate the influence of diabetes mellitus on the serum concentrations of rifampicin in a cohort of patients under treatment with anti-tuberculosis drugs. After fasting of 12 hours, the concentrations of rifampicin, blood glucose levels, and glycated hemoglobin levels were measured at 1h after the ingestion of 600 mg of rifampicin. A total of 49 patients were included in the study and allocated in the TB group (n=36) and TB-DM group (n=13). The dose administered of rifampicin was similar in both groups, with median values of 9,82mg/kg and 10,14mg/kg in TB and TB-DM groups. The median serum concentrations of rifampicin in the intensive phase of treatment were 6,83µg/ml e 2,2µg/ml and in the continuation, were 2,75µg/ml and 2,48µg/ml, in TB and TB-DM groups. Approximately 12,25% of study patients presented rifampicin serum levels above the recommended value (8µg/ml). The concentrations of rifampicin were similar in TB and TB-DM groups in both treatment phases, but TB group present significant high levels of the drug in the acute phase of treatment. Moreover, the concentrations of rifampicin did not correlate significantly with glucose levels and glycated hemoglobin levels in both groups. Diabetes Mellitus did not provoke significant changes in serum rifampicin concentrations, but the treatment phase had a significant impact on drug levels.